PHARMACARE FINANCE PLC BONDS ISSUE IS NOW CLOSED DUE TO OVER SUBSCRIPTION
Pharmacare Finance Plc has announced the issue of €5,000,000 of 5.75% Unsecured Bonds redeemable between 2025 and 2028, with a nominal value of €100 issued at par.
If you wish to apply for these bonds see information at the bottom of this article or contact us on +356 25 688 888.
The primary activity of Pharmacare Finance Plc, is limited to the raising of capital for the financing of projects and the loaning of such funds to Pharmacare Premium.
Pharmacare Premium develops, registers, manufactures and supplies pharmaceutical products. It owns and operates a fully licensed state-of the-art facility in Hal Far specialised in the handling of highly-potent molecules, which are medicines used in cancer treatments and other niche therapeutic categories.
USE OF PROCEEDS:
The proceeds from the Bond Issue, will be used by the Issuer for the following purposes and in order of priority set out below:
A. Approx. €4,000,000 (or 80% of the net proceeds from the Bond Issue) will be advanced by the Issuer for the purpose of funding 5 product development projects. These projects include the following activities:
i. Formulation development and reference samples
ii. Intellectual Property research and assessment
iii. Clinical trials (Bio-equivalent studies)
iv. Production of trial, registration and validation batches
v. Purchasing of any needed equipment and change-parts
vi. Purchasing of raw materials (especially Active Pharmaceutical Ingredients)
vii. Dossier compilation and registration (regulatory affairs)
B. Up to €1,000,000 (or 20% of net proceeds from the Bond Issue) will be advanced by the Issuer to the Guarantor for the financing of overheads and general expenses.
Pharmacare Premium is a pharmaceutical manufacturing company located in Malta enabling it to offer unique services covering a strategic base for the development of generics and for ‘Day 1’ launch into the EU and beyond.
Established in Malta in 2010, with a considerable investment of founding energy, expertise, and resources, Pharmacare Premium boasts a state-of-the-art facility, infrastructure and high-end equipment, dedicated for high potency ‘contained production’ to supply a range of therapeutic products for world markets.
Pharmacare Premium’s modern facility is an EU-GMP approved site, equipped with ‘leading technology’ machinery and equipment, which together with an expert team of industry professionals, ensure optimum and quality level of performance in delivery.
Malta’s favourable patent landscape, along with Pharmacare’s capability to handle difficult-to-produce, niche products, are key factors in the unique position of Pharmacare and its solid growth drive.
Pharmacare Premium has started its own product developments in order to leverage these unique competitive advantages and offer high value products to its professional network in Europe, Latin America, CIS countries and the Middle East and North Africa (MENA) region.
APPLICATION HAS BEEN MADE TO THE EXCHANGE FOR THE BONDS TO BE ADMITTED TO TRADING ON PROSPECTS MTF. PROSPECTS IS A MARKET DESIGNED PRIMARILY FOR EMERGING AND SMALLER COMPANIES TO WHICH A HIGHER INVESTMENT RISK TENDS TO BE ATTACHED. PROSPECTS MTF SECURITIES ARE NOT ADMITTED TO THE OFFICIAL LIST OF THE MALTA STOCK EXCHANGE.
HOW TO REGISTER TO BUY BONDS?
Orders will be accepted from Friday, 19th of October 2018.
All orders must be submitted by not later than Friday, 26th of October @ 12:00 pm (Closing date)
Important – The offer may close at an earlier date due to over-subscription.
Applications must be for a minimum value of €2,000 and multiples of €100.
A copy of the admission document is available HERE
Orders may be placed by contacting us on +356 25 688 888 or via email on [email protected] or through your finance advisor.
Calamatta Cuschieri Investment Services Ltd is acting as Corporate Advisor, Placement Agent and Manager for this bond issue.